NTLA
Intellia TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The April 27 HAELO readout is a real thesis change: Intellia now has positive Phase 3 data, a rolling BLA has started, and the April financing pushes runway at least into 2028, which together meaningfully de-risk the path to a first launch.
Posture
Defensive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Equity dilution from the April 2026 follow-on offering may cap near-term upside even after the positive HAELO readout.
Momentum
17
Value
41
Sentiment
65
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $15.00 · Bull $21.00 · Bear $8.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $25.20
Why
Momentum17 · Δ7d +10.3
Value41 · Δ7d +0.1
Sentiment65 · Δ7d -6.5
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
17
34% active weight
Current posture
7d trendImproving
Δ7d
+10.3
Δ21d
-44.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
65
33% active weight
Current posture
7d trendSoftening
Δ7d
-6.5
Δ21d
+13.6
Why this grade
Composite grade D. Momentum 16.9 / Value 41.1 / Sentiment 64.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.92B
Beta
2.09
Shares Out
115.83M
P/E (TTM) · Derived
-4.3
P/S (TTM)
18.87
P/FCF (TTM) · Derived
-4.21
Rev YoY
+51.3%
EPS YoY
+31.6%
Gross Margin
-
Op Margin
-832.2%
Net Debt
-$601.52M
Current Ratio
6.21
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology